scholarly journals Clinical Translation of Mesenchymal Stromal Cell Therapy for Graft Versus Host Disease

2019 ◽  
Vol 7 ◽  
Author(s):  
Juliana A. P. Godoy ◽  
Raquel M. A. Paiva ◽  
Aline M. Souza ◽  
Andrea T. Kondo ◽  
Jose M. Kutner ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Graft Versus Host Disease ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Clinical Translation ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

2014 ◽  
Vol 20 (10) ◽  
pp. 1580-1585 ◽  
Author(s):  
Fermín Sánchez-Guijo ◽  
Teresa Caballero-Velázquez ◽  
Olga López-Villar ◽  
Alba Redondo ◽  
Rocío Parody ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Graft Versus Host Disease ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Third Party ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

2011 ◽  
Vol 95 (2) ◽  
pp. 182-188 ◽  
Author(s):  
Richard Herrmann ◽  
Marian Sturm ◽  
Kathryn Shaw ◽  
Duncan Purtill ◽  
Julian Cooney ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Graft Versus Host Disease ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Refractory

scholarly journals Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Caroline Gavin ◽  
Erik Boberg ◽  
Lena Von Bahr ◽  
Matteo Bottai ◽  
Anton Törnqvist Andrén ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Immune Cell ◽  
Therapeutic Potential ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Profile ◽  
Acute Graft

AbstractAcute graft-versus-host disease (aGvHD), post-allogeneic hematopoietic stem cell transplantation, is associated with high mortality rates in patients not responding to standard line care with steroids. Adoptive mesenchymal stromal cell (MSC) therapy has been established in some countries as a second-line treatment.Limitations in our understanding as to MSC mode of action and what segregates patient responders from non-responders to MSC therapy remain. The principal aim of this study was to evaluate the immune cell profile in gut biopsies of patients diagnosed with aGvHD and establish differences in baseline cellular composition between responders and non-responders to subsequent MSC therapy.Our findings indicate that a pro-inflammatory immune profile within the gut at the point of MSC treatment may impede their therapeutic potential. These findings support the need for further validation in a larger cohort of patients and the development of improved biomarkers in predicting responsiveness to MSC therapy.

Sign in / Sign up

Export Citation Format

Share Document